Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: sarilumab Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 28, 2026, 10:24 PM EDT
Not listed Phase 3 Interventional

Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics

NCT03535402
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab
Drug
Lead sponsor
Gaylis, Norman B., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 28, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

NCT03770273
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
sarilumab, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 28, 2026, 10:24 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

NCT03600818
View directory record Official record
Conditions
Polymyalgia Rheumatica
Interventions
Sarilumab SAR153191 (REGN88), Sarilumab-matching placebo, Prednisone, Prednisone-matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Upland, California • Denver, Colorado • Stamford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 28, 2026, 10:24 PM EDT
Terminated Phase 3 Interventional Results available

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

NCT01764997
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 28, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional Results available

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

NCT01217814
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Placebo, Golimumab, methotrexate (MTX), Folic/folinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 28, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 28, 2026, 10:24 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Assess Sarilumab in Halting Progression of Morphea

NCT03679845
View directory record Official record
Conditions
Morphea, Plaque Form
Interventions
Sarilumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 28, 2026, 10:24 PM EDT
Completed No phase listed Observational

Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments

NCT05638932
View directory record Official record
Conditions
COVID-19
Interventions
Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
Drug
Lead sponsor
Aetion, Inc.
Other
Eligibility
18 Years and older
Enrollment
1,442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients

NCT01328522
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR153191 (REGN88)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Beverly Hills, California • Ocala, Florida • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Sep 28, 2026, 10:24 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

NCT05535738
View directory record Official record
Conditions
Skin Inflammation, Allergic Contact Dermatitis
Interventions
Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy
Drug · Other · Device + 1 more
Lead sponsor
Wei-Che Ko
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 28, 2026, 10:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

NCT04333706
View directory record Official record
Conditions
Breast, Metastatic, Triple Negative, Cancer, Disseminated Tumor Cell
Interventions
Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine
Drug · Combination Product
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 28, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional Results available

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

NCT01118728
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Sarilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 28, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Sarilumab for Patients With Moderate COVID-19 Disease

NCT04359901
View directory record Official record
Conditions
COVID
Interventions
SARILUMAB
Biological
Lead sponsor
Westyn Branch-Elliman
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
West Haven, Connecticut • Augusta, Maine • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 28, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

NCT06787612
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 28, 2026, 10:24 PM EDT
Recruiting Phase 3 Interventional

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

NCT03414502
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 28, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT05428007
View directory record Official record
Conditions
Melanoma, Unresectable Melanoma
Interventions
Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 28, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

NCT02097524
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 28, 2026, 10:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

NCT01061736
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Placebo (for sarilumab), Methotrexate, Folic Acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 28, 2026, 10:24 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

NCT05704634
View directory record Official record
Conditions
Lung Cancer
Interventions
Cemiplimab, Kevzara (Sarilumab)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 28, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

NCT01055899
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
REGN88
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 28, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

NCT02776735
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Sarilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 28, 2026, 10:24 PM EDT
Not yet recruiting Phase 2 Interventional

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

NCT07836101
View directory record Official record
Conditions
Any Advanced Solid Tumors
Interventions
Sarilumab, ICI Therapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 28, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

NCT01768572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 28, 2026, 10:24 PM EDT